WBO:MOR (Germany)  
MorphoSys AG logo

MorphoSys AG

€ 18.29 (-1.75%) Sep 23
P/E:
At Loss
P/B:
0
Market Cap:
€ 620.57M ($ 597.74M)
Enterprise V:
€ 225.68M ($ 217.38M)
Volume:
-
Avg Vol (2M):
362.00
Also Trade In:
Volume:
-
Market Cap €:
620.57M
Market Cap $:
597.74M
PE Ratio:
At Loss
Avg Vol (2-Month):
362.00
Enterprise Value €:
225.68M
Enterprise Value $:
217.38M
PB Ratio:
0
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Name Current Vs Industry Vs History
Cash-To-Debt 2.19
Equity-to-Asset -0.01
Debt-to-Equity -12.09
Debt-to-EBITDA -0.53
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.89
Distress
Grey
Safe
Beneish M-Score -1.1
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 27.32
9-Day RSI 39.19
14-Day RSI 42.1
6-1 Month Momentum % -20.39
12-1 Month Momentum % -54.88

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.98
Quick Ratio 2.91
Cash Ratio 2.29
Days Inventory 160.85
Days Sales Outstanding 166.39
Days Payable 639.05

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.7

Financials (Next Earnings Date:2022-11-10 Est.)

WBO:MOR's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 195.096
EPS (TTM) (€) -24.93
Beta 0.42
Volatility % 36.68
14-Day RSI 42.1
14-Day ATR (€) 0.576927
20-Day SMA (€) 18.41225
12-1 Month Momentum % -54.88
52-Week Range (€) 16.265 - 42.73
Shares Outstanding (Mil) 34.15

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

MorphoSys AG Filings

Document Form Filing Date
No Filing Data

MorphoSys AG Analysis

Share your research